MicroRNAs and Cancer Resistance: A New Molecular Plot
MicroRNAs and Cancer Resistance: A New Molecular Plot
复制标题
DOI：
10.1002/cpt.353
复制
发表时间：
2016-05-01
影响因子：
6.7
通讯作者：
Fabbri, M.
中科院分区：
文献类型：
--
作者：
Fanini, F.;Fabbri, M.
癌症复发的最常见原因是获得性或内在的耐药性，这严重限制了传统和新的靶向化疗的疗效。MicroRNAs(MiRNAs)是一个不断发展壮大的非编码短小RNA家族，在恶性肿瘤中经常发生异常调节。虽然miRNA介导的耐药机制还不完全清楚，但越来越多的证据表明，它们参与了肿瘤细胞耐药性的获得，这表明需要新的、更具创新性的治疗方法。使用对映体或模拟物可以调节特定的miRNAs，以恢复基因网络和信号通路，或许可以通过增加癌细胞对药物的敏感性来优化化疗。这篇综述的目的是提供关于参与癌症治疗耐药过程的miRNAs领域的最新发现的最新情况。
The most common cause of cancer relapse is drug resistance, acquired or intrinsic, which strongly limits the efficacy of both conventional and new targeted chemotherapy. MicroRNAs (miRNAs) are a growing, large family of short noncoding RNAs frequently dysregulated in malignancies. Although the mechanism of miRNA-mediated drug resistance is not fully understood, an increasing amount of evidence suggests their involvement in the acquisition of tumor cell drug resistance, pointing towards the need for novel and more innovative therapeutic approaches. Use of antagomiRs or mimics can modulate specific miRNAs in order to restore gene networks and signaling pathways, perhaps optimizing chemotherapies by increasing cancer cell sensitivity to drugs. The aim of this review is to provide a state-of-the-art scenario with regard to the most recent discoveries in the field of miRNAs involved in the process of resistance to cancer therapy.